



() -

*

*

5HT1A

(Nepean Dyspepsia Index) NDI

// : - // :

-

.() .()

.() ()

5HT1A ()

. .

(Tack) .() .()

.()

(Boeckxstaens)

. .

.() .()

(5HT1)

()

-

() .

() - -

. .

. .

.()

SPSS

(SPSS Inc., Chicago, IL, USA)

()

/

)

(

(/)

(Alarm Features)

/ (± /)

(/)

(/)

(/)

(/)

/ ± /

Nepean) NDI

/ ± /

()

(Dyspepsia Index

/ ± /

/ ± /

/ ±

/ ± /

(p< /)

.(p< /) / ± / / ± /

/ ± /

(p< /) / ± / / ± /

/ ±

:

< /	/ (/)	/ (/) < /	/ (/)	/ (/) < /	/ (/)	/ (/)*
NS	/ (/)	(/) < /	/ (/)	/ (/) < /	/ (/)	/ (/)
NS	/ (/)	/ (/) < /	/ (/)	(/) < /	/ (/)	(/)
< /	/ (/)	/ (/) < /	/ (/)	/ (/) < /	/ (/)	/ (/)
< /	/ (/)	/ (/) < /	(/)	(/) < /	/ (/)	/ (/)
< /	/ (/)	/ (/) < /	/ (/)	/ (/) < /	/ (/)	/ (/)
< /	/ (/)	/ (/) NS	/ (/)	/ (/) NS	/ (/)	/ (/)
< /	/ (/)	(/) < /	/ (/)	/ (/) < /	/ (/)	/ (/)
< /	(/)	/ (/) < /	/ (/)	/ (/) < /	/ (/)	/ (/)
< /	/ (/)	/ (/) < /	/ (/)	/ (/) < /	/ (/)	/ (/)
< /	/ (/)	/ (/) < /	/ (/)	/ (/) < /	(/)	/ (/)
< /	(/)	/ (/) < /	(/)	/ (/) < /	/ (/)	/ (/)
< /	(/)	/ (/) < /	/ (/)	/ (/) < /	/ (/)	/ (/)
NS	(/)	(/) NS	/ (/)	/ (/) NS	/ (/)	(/)
< /	(/)	/ (/) < /	/ (/)	/ (/) < /	/ (/)	(/)

. () *

.(P = /)

(P < /)

- (P< /) - (P< /)

(P< /) (P< /) (P< /)

(P< /)

(P< /)

(P< /)

(P< /)

•

(

(

(

(

•

.()

· ()

.()

)

(

()

(Chial)

.()

.()

.()

5HT1A

.()

-

.()

.()

()

5HT1A

()

5HT2

5HT1A

.()

()

(Alander)

()

()

()

()

()

()

()

(Ahlawat)

.()

()

.()

References:

1. Chua AS. Reassessment of functional dyspepsia: a topic review. *World J Gastroenterol* 2006; 12:2656-9.
2. Baker G, Fraser RJ, Young G. Subtypes of functional dyspepsia. *World J Gastroenterol* 2006; 12:2667-71.
3. Simren M, Tack J. Functional dyspepsia: evaluation and treatment. *Gastroenterol Clin North Am* 2003; 32:577-99.
4. O'Mahony S, Dinan TG, Keeling PW, et al. Central serotonergic and noradrenergic receptors in functional dyspepsia. *World J Gastroenterol* 2006;12:2681-7.
5. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. *Am J Med* 2000;108:65-72.
6. Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. *Am J Gastroenterol* 1998;93:160-5.
7. Tack J, Sarnelli G. Serotonergic modulation of visceral sensation: upper gastrointestinal tract. *Gut* 2002;51 Suppl 1:i77-80.
8. Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. *Gastroenterology* 1998;115:1346-52.
9. Boeckxstaens GE. Neuroimmune interaction in the gut: from bench to bedside. *Verh K Acad Geneeskd Belg* 2006; 68:329-55.
10. Tack J, Coulie B, Wilmer A, et al. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. *Gut* 2000; 46:468-73.
11. Vingerhagen S, Hausken T, Gilja OH, et al. Influence of a 5HT₁ receptor agonist on gastric accommodation and initial transpyloric flow in healthy subjects. *Neurogastroenterol Motil* 2000; 12:95-101.
12. Dickerson LM, King DE. Evaluation and management of nonulcer dyspepsia. *Am Fam Physician* 2004; 70:107-14.
13. Talley NJ, Verlinden M, Jones M. Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index. *Am J Gastroenterol* 1999; 94: 2390-7.
14. Talley NJ, Haque M, Wyeth JW, et al. Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. *Aliment Pharmacol Ther* 1999; 13: 225-35.
15. Salet GA, Samsom M, Roelofs JM, et al. Responses to gastric distension in functional dyspepsia. *Gut* 1998;42:823-9.
16. Tack J. Functional Dyspepsia: Impaired Fundic Accommodation. *Curr Treat Options Gastroenterol* 2000;3:287-93.
17. Troncon LE. New drugs for the treatment of functional dyspepsia. *Arq Gastroenterol* 2001;38:207-12.
18. Chial HJ, Camilleri M, Ferber I, et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. *Clin Gastroenterol Hepatol* 2003; 1:211-8.
19. Berstad A, Olafsson S, Tefera S, et al. Controversies in dyspepsia. *Eur J Surg Suppl* 2001; 586:4-11.
20. Glitz DA, Pohl R. 5-HT_{1A} partial agonists. What is their future? *Drugs* 1991;41:11-8.
21. Marsden CA. The pharmacology of new anxiolytics acting on 5-HT neurones. *Postgrad Med J* 1990;66 Suppl 2:S2-6.
22. Meltzer HY, Flemming R, Robertson A. The effect of buspirone on prolactin and growth hormone secretion in man. *Arch Gen Psychiatry* 1983;40:1099-102.
23. Ahlawat SK, Cuddihy MT, Locke GR 3rd. Gender-related differences in dyspepsia: a qualitative systematic review. *Gend Med* 2006;3:31-42.
24. Quartero AO, Post MW, Numans ME, et al. What makes the dyspeptic patient feel ill? A cross sectional survey of functional health status, *Helicobacter pylori* infection, and psychological distress in dyspeptic patients in general practice. *Gut* 1999;45:15-9.
25. Wamala S, Merlo J, Bostrom G, et al. Perceived discrimination, socioeconomic disadvantage and refraining from seeking medical treatment in Sweden. *J Epidemiol Community Health* 2007;61:409-15.
26. Afifi M. Gender differences in mental health. *Singapore Med J* 2007;48:385-91.
27. Alander T, Svardsudd K, Johansson SE, et al. Psychological illness is commonly associated with functional gastrointestinal disorders and is important to consider during patient consultation: a population-based study. *BMC Med* 2005;3:8.